Double stranded DNA (dsDNA)
|
n.a.
|
Indirect ELISA
|
No significant difference in anti-dsNDA IgE levels between
ASST+ and ASST- patients
No correlation with total IgE and disease duration
|
Yes, no difference between CSU and HC
|
67
|
Eosinophil cationic protein |
5.4 |
Direct ELISA after IgG
depletion |
n.a. |
n.a. |
59 |
Eosinophil Peroxidase |
10.9 |
Direct ELISA after IgG depletion |
n.a. |
n.a. |
59 |
FcεRI |
30 |
Sandwich ELISA |
n.a. |
Yes, significantly higher
in CSU than HC |
68 |
Interleukin 24
(IL-24)
|
80
|
Microarray and Sandwich ELISA
|
Positive correlation with disease activity (UAS7)
Negative correlation with blood basophil counts
|
None of the patients assessed via microarray had detectable
IgG-anti-IL-24
|
69
|
|
31
|
Site direct ELISA
|
Patients with IgE autoantibodies (anti-TPO and anti-IL-24) had higher
anti-TPO IgG and lower IgE and leukocyte counts compared to CSU
patients without autoantibodies
|
n.a.
|
53
|
Thyroglobulin (TG) |
5 |
Modified commercial ELISA |
n.a. |
yes |
60 |
|
7
|
ELISA kit
|
No difference in disease duration, UASday and total IgE between
patients with and without Anti-TG-IgE
|
Yes, correlation of IgE autoantibodies and IgG autoantibodies
|
61
|
|
35 |
Sandwich ELISA |
n.a. |
Yes, no differences between CSU and HC |
68 |
|
87
|
Sandwich ELISA
|
Anti-TG IgE levels dropped 1 week after omalizumab administration
This drop was correlated with drop in UAS 7 at 1 week and 2 months
|
Yes, most patients negative
|
70
|
Thyroidperoxidase (TPO)
|
54
|
Site-directed human IgE capture ELISA
|
No differences in disease duration, UAS, DLQI and total IgE between
CSU patients with and without anti-TPO IgE
CSU patients with anti-TPO IgE had higher anti-TPO IgG levels,
lymphocyte numbers and complement C4
|
Yes, CSU patients with anti-TPO IgE had significantly higher anti-TPO
IgG
|
57
|
|
7,5* |
Direct ELISA |
n.a. |
yes |
72 |
|
27,2 |
Direct ELISA after IgG depletion |
n.a. |
n.a. |
59 |
|
34
|
Direct ELISA after IgG depletion
|
No differences in UAS, DLQI, anti-TPO IgG and total IgE between CSU
with IgE-anti-TPO and patients without
|
yes
|
58
|
|
5 |
Modified commercial ELISA |
n.a. |
yes |
60 |
|
18
|
ELISA kit
|
No difference in disease duration, UASday between CSU with anti-TPO
IgE and patients without
Lower total IgE levels and antihistamine-refractory cases in patients
with anti-TPO IgE
|
Yes, Significant correlation of IgE autoantibodies and IgG
autoantibodies
|
61
|
|
43
|
Direct ELISA after IgG depletion
|
More patients with anti-TPO IgE had asthma, atopy (to mites and/or
pets) and NSAID reaction than patients without anti-TPO IgE
Patients with anti-TPO IgE had lower total IgE levels than patients
without anti-TPO IgE
No difference between age of onset, DLQI score, UAS score
|
n.a.
|
62
|
|
100 |
Side direct ELISA |
n.a. |
Yes |
63 |
|
0 |
Modified commercial radioimmunoassay |
n.a. |
Yes |
64 |
|
41
|
Side direct ELISA
|
Patients with IgE autoantibodies (anti TPO and IL-24) had higher
anti-TPO IgG and lower IgE and leukocyte counts compared to patients
without
|
Yes
|
53
|
Tissue Factor (TF)
|
50
|
Sandwich ELISA
|
Omalizumab late responders had significantly higher anti-TF IgE levels
than early responders
|
Yes, higher in CSU than HC and higher in omalizumab late responders than
early responders
|
68
|
|
60
|
Sandwich ELISA
|
Levels dropped 1 week after omalizumab administration
This drop was correlated with drop in UAS 7 at 2 months
|
n.a.
|
70
|
Tissue Transglutaminase 2 (TG2)
|
20.6
|
Capture ELISA
|
Not linked to any demographic, clinical and laboratory features of CSU
including the presence of previously described anti-TPO and anti-IL-24
IgE
|
n.a.
|
71
|